APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psoriasis Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Psoriasis Biosimilar Market Outlook and Growth Opportunities 2026

27 December 2025198 pages

Choose your research edition.

Industry ResearchPsoriasis Biosimilar Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Psoriasis Biosimilar Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Psoriasis Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psoriasis Biosimilar Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Psoriasis Biosimilar Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Psoriasis Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Psoriasis Biosimilar market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Psoriasis Biosimilar market include Amgen Inc, Celltrion, Coherus BioSciences, Fresenius Kabi, GenScript, Gyros Protein Technologies AB, Hoffmann-La Roche Ltd, Novartis International AG and Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Psoriasis Biosimilar market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Psoriasis Biosimilar and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Psoriasis Biosimilar revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Psoriasis Biosimilar market.

Psoriasis Biosimilar Segment by Company

Amgen Inc

Celltrion

Coherus BioSciences

Fresenius Kabi

GenScript

Gyros Protein Technologies AB

Hoffmann-La Roche Ltd

Novartis International AG

Reddy's Laboratories

Samsung Bioepis

Samsung Bioepis Co., Ltd.

Viatris

Pfizer Inc.

Merck KGaA

Sandoz

Psoriasis Biosimilar Segment by Type

TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)

Other Biosimilars

Psoriasis Biosimilar Segment by Application

Plaque Psoriasis

Psoriatic Arthritis

Other

Psoriasis Biosimilar Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Psoriasis Biosimilar status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Psoriasis Biosimilar key companies, revenue, market share, and recent developments.

3. To split the Psoriasis Biosimilar breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Psoriasis Biosimilar market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Psoriasis Biosimilar significant trends, drivers, influence factors in global and regions.

6. To analyze Psoriasis Biosimilar competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriasis Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psoriasis Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriasis Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psoriasis Biosimilar industry.

Chapter 3: Detailed analysis of Psoriasis Biosimilar company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Psoriasis Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Psoriasis Biosimilar in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Psoriasis Biosimilar Industry Trends Table 2. Psoriasis Biosimilar Industry Drivers Table 3. Psoriasis Biosimilar Industry Opportunities and Challenges Table 4. Psoriasis Biosimilar Industry Restraints Table 5. Global Psoriasis Biosimilar Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Psoriasis Biosimilar Revenue Share by Company (2021-2026) Table 7. Global Psoriasis Biosimilar Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Psoriasis Biosimilar Key Company Manufacturing Base & Headquarters Table 9. Global Psoriasis Biosimilar Company, Product Type & Application Table 10. Global Psoriasis Biosimilar Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Psoriasis Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab) Table 15. Significant Companies of Other Biosimilars Table 16. Global Psoriasis Biosimilar Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Psoriasis Biosimilar Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Psoriasis Biosimilar Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Psoriasis Biosimilar Sales Value Share by Type (2021-2026) Table 20. Global Psoriasis Biosimilar Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Plaque Psoriasis Table 22. Significant Companies of Psoriatic Arthritis Table 23. Significant Companies of Other Table 24. Global Psoriasis Biosimilar Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Psoriasis Biosimilar Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Psoriasis Biosimilar Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Psoriasis Biosimilar Sales Value Share by Application (2021-2026) Table 28. Global Psoriasis Biosimilar Sales Value Share by Application (2027-2032) Table 29. Global Psoriasis Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Psoriasis Biosimilar Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Psoriasis Biosimilar Sales Value Share by Region (2021-2026) Table 32. Global Psoriasis Biosimilar Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Psoriasis Biosimilar Sales Value Share by Region (2027-2032) Table 34. Global Psoriasis Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Psoriasis Biosimilar Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Psoriasis Biosimilar Sales Value Market Share by Country (2021-2026) Table 37. Global Psoriasis Biosimilar Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Psoriasis Biosimilar Sales Value Market Share by Country (2027-2032) Table 39. Amgen Inc Company Information Table 40. Amgen Inc Business Overview Table 41. Amgen Inc Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Amgen Inc Psoriasis Biosimilar Product Portfolio Table 43. Amgen Inc Recent Development Table 44. Celltrion Company Information Table 45. Celltrion Business Overview Table 46. Celltrion Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Celltrion Psoriasis Biosimilar Product Portfolio Table 48. Celltrion Recent Development Table 49. Coherus BioSciences Company Information Table 50. Coherus BioSciences Business Overview Table 51. Coherus BioSciences Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Coherus BioSciences Psoriasis Biosimilar Product Portfolio Table 53. Coherus BioSciences Recent Development Table 54. Fresenius Kabi Company Information Table 55. Fresenius Kabi Business Overview Table 56. Fresenius Kabi Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Fresenius Kabi Psoriasis Biosimilar Product Portfolio Table 58. Fresenius Kabi Recent Development Table 59. GenScript Company Information Table 60. GenScript Business Overview Table 61. GenScript Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. GenScript Psoriasis Biosimilar Product Portfolio Table 63. GenScript Recent Development Table 64. Gyros Protein Technologies AB Company Information Table 65. Gyros Protein Technologies AB Business Overview Table 66. Gyros Protein Technologies AB Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio Table 68. Gyros Protein Technologies AB Recent Development Table 69. Hoffmann-La Roche Ltd Company Information Table 70. Hoffmann-La Roche Ltd Business Overview Table 71. Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio Table 73. Hoffmann-La Roche Ltd Recent Development Table 74. Novartis International AG Company Information Table 75. Novartis International AG Business Overview Table 76. Novartis International AG Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis International AG Psoriasis Biosimilar Product Portfolio Table 78. Novartis International AG Recent Development Table 79. Reddy's Laboratories Company Information Table 80. Reddy's Laboratories Business Overview Table 81. Reddy's Laboratories Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Reddy's Laboratories Psoriasis Biosimilar Product Portfolio Table 83. Reddy's Laboratories Recent Development Table 84. Samsung Bioepis Company Information Table 85. Samsung Bioepis Business Overview Table 86. Samsung Bioepis Psoriasis Biosimilar Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Samsung Bioepis Psoriasis Biosimilar Product Portfolio Table 88. Samsung Bioepis Recent Development Table 89. Samsung Bioepis Co., Ltd. Company Information Table 90. Samsung Bioepis Co., Ltd. Business Overview Table 91. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio Table 93. Samsung Bioepis Co., Ltd. Recent Development Table 94. Viatris Company Information Table 95. Viatris Business Overview Table 96. Viatris Psoriasis Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Viatris Psoriasis Biosimilar Product Portfolio Table 98. Viatris Recent Development Table 99. Pfizer Inc. Company Information Table 100. Pfizer Inc. Business Overview Table 101. Pfizer Inc. Psoriasis Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Pfizer Inc. Psoriasis Biosimilar Product Portfolio Table 103. Pfizer Inc. Recent Development Table 104. Merck KGaA Company Information Table 105. Merck KGaA Business Overview Table 106. Merck KGaA Psoriasis Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Merck KGaA Psoriasis Biosimilar Product Portfolio Table 108. Merck KGaA Recent Development Table 109. Sandoz Company Information Table 110. Sandoz Business Overview Table 111. Sandoz Psoriasis Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Sandoz Psoriasis Biosimilar Product Portfolio Table 113. Sandoz Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Psoriasis Biosimilar Product Image Figure 2. Global Psoriasis Biosimilar Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psoriasis Biosimilar Market Size (2021-2032) & (US$ Million) Figure 4. Global Psoriasis Biosimilar Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab) Image Figure 8. Other Biosimilars Image Figure 9. Global Psoriasis Biosimilar Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Psoriasis Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Psoriasis Biosimilar Sales Value Share by Type (2021-2032) Figure 12. Plaque Psoriasis Image Figure 13. Psoriatic Arthritis Image Figure 14. Other Image Figure 15. Global Psoriasis Biosimilar Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Psoriasis Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Psoriasis Biosimilar Sales Value Share by Application (2021-2032) Figure 18. Global Psoriasis Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Psoriasis Biosimilar Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Psoriasis Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 21. North America Psoriasis Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Psoriasis Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Psoriasis Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Psoriasis Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Psoriasis Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Psoriasis Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 27. South America Psoriasis Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Psoriasis Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Psoriasis Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Psoriasis Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
  • Other Biosimilars
Applications
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Other
Companies covered
  • Amgen Inc
  • Celltrion
  • Coherus BioSciences
  • Fresenius Kabi
  • GenScript
  • Gyros Protein Technologies AB
  • Hoffmann-La Roche Ltd
  • Novartis International AG
  • Reddy's Laboratories
  • Samsung Bioepis
  • Samsung Bioepis Co., Ltd.
  • Viatris
  • Pfizer Inc.
  • Merck KGaA
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Psoriasis Biosimilar Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Psoriasis Biosimilar Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Psoriasis Biosimilar Market Dynamics
  1. 2.1 Psoriasis Biosimilar Industry Trends
  2. 2.2 Psoriasis Biosimilar Industry Drivers
  3. 2.3 Psoriasis Biosimilar Industry Opportunities and Challenges
  4. 2.4 Psoriasis Biosimilar Industry Restraints
3 Psoriasis Biosimilar Market by Company
  1. 3.1 Global Psoriasis Biosimilar Company Revenue Ranking in 2025
  2. 3.2 Global Psoriasis Biosimilar Revenue by Company (2021-2026)
  3. 3.3 Global Psoriasis Biosimilar Company Ranking (2024-2026)
  4. 3.4 Global Psoriasis Biosimilar Company Manufacturing Base and Headquarters
  5. 3.5 Global Psoriasis Biosimilar Company Product Type and Application
  6. 3.6 Global Psoriasis Biosimilar Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Psoriasis Biosimilar Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Psoriasis Biosimilar Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Psoriasis Biosimilar Market by Type
  1. 4.1 Psoriasis Biosimilar Type Introduction
  2. 4.1.1 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
  3. 4.1.2 Other Biosimilars
  4. 4.2 Global Psoriasis Biosimilar Sales Value by Type
  5. 4.2.1 Global Psoriasis Biosimilar Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Psoriasis Biosimilar Sales Value by Type (2021-2032)
  7. 4.2.3 Global Psoriasis Biosimilar Sales Value Share by Type (2021-2032)
5 Psoriasis Biosimilar Market by Application
  1. 5.1 Psoriasis Biosimilar Application Introduction
  2. 5.1.1 Plaque Psoriasis
  3. 5.1.2 Psoriatic Arthritis
  4. 5.1.3 Other
  5. 5.2 Global Psoriasis Biosimilar Sales Value by Application
  6. 5.2.1 Global Psoriasis Biosimilar Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Psoriasis Biosimilar Sales Value by Application (2021-2032)
  8. 5.2.3 Global Psoriasis Biosimilar Sales Value Share by Application (2021-2032)
6 Psoriasis Biosimilar Regional Value Analysis
  1. 6.1 Global Psoriasis Biosimilar Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Psoriasis Biosimilar Sales Value by Region (2021-2032)
  3. 6.2.1 Global Psoriasis Biosimilar Sales Value by Region: 2021-2026
  4. 6.2.2 Global Psoriasis Biosimilar Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Psoriasis Biosimilar Sales Value (2021-2032)
  7. 6.3.2 North America Psoriasis Biosimilar Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Psoriasis Biosimilar Sales Value (2021-2032)
  10. 6.4.2 Europe Psoriasis Biosimilar Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Psoriasis Biosimilar Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Psoriasis Biosimilar Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Psoriasis Biosimilar Sales Value (2021-2032)
  16. 6.6.2 South America Psoriasis Biosimilar Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Psoriasis Biosimilar Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Psoriasis Biosimilar Sales Value Share by Country, 2025 VS 2032
7 Psoriasis Biosimilar Country-level Value Analysis
  1. 7.1 Global Psoriasis Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Psoriasis Biosimilar Sales Value by Country (2021-2032)
  3. 7.2.1 Global Psoriasis Biosimilar Sales Value by Country (2021-2026)
  4. 7.2.2 Global Psoriasis Biosimilar Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Psoriasis Biosimilar Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Psoriasis Biosimilar Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Psoriasis Biosimilar Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen Inc
  2. 8.1.1 Amgen Inc Company Information
  3. 8.1.2 Amgen Inc Business Overview
  4. 8.1.3 Amgen Inc Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
  6. 8.1.5 Amgen Inc Recent Developments
  7. 8.2 Celltrion
  8. 8.2.1 Celltrion Company Information
  9. 8.2.2 Celltrion Business Overview
  10. 8.2.3 Celltrion Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Celltrion Psoriasis Biosimilar Product Portfolio
  12. 8.2.5 Celltrion Recent Developments
  13. 8.3 Coherus BioSciences
  14. 8.3.1 Coherus BioSciences Company Information
  15. 8.3.2 Coherus BioSciences Business Overview
  16. 8.3.3 Coherus BioSciences Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
  18. 8.3.5 Coherus BioSciences Recent Developments
  19. 8.4 Fresenius Kabi
  20. 8.4.1 Fresenius Kabi Company Information
  21. 8.4.2 Fresenius Kabi Business Overview
  22. 8.4.3 Fresenius Kabi Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
  24. 8.4.5 Fresenius Kabi Recent Developments
  25. 8.5 GenScript
  26. 8.5.1 GenScript Company Information
  27. 8.5.2 GenScript Business Overview
  28. 8.5.3 GenScript Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GenScript Psoriasis Biosimilar Product Portfolio
  30. 8.5.5 GenScript Recent Developments
  31. 8.6 Gyros Protein Technologies AB
  32. 8.6.1 Gyros Protein Technologies AB Company Information
  33. 8.6.2 Gyros Protein Technologies AB Business Overview
  34. 8.6.3 Gyros Protein Technologies AB Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
  36. 8.6.5 Gyros Protein Technologies AB Recent Developments
  37. 8.7 Hoffmann-La Roche Ltd
  38. 8.7.1 Hoffmann-La Roche Ltd Company Information
  39. 8.7.2 Hoffmann-La Roche Ltd Business Overview
  40. 8.7.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
  42. 8.7.5 Hoffmann-La Roche Ltd Recent Developments
  43. 8.8 Novartis International AG
  44. 8.8.1 Novartis International AG Company Information
  45. 8.8.2 Novartis International AG Business Overview
  46. 8.8.3 Novartis International AG Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
  48. 8.8.5 Novartis International AG Recent Developments
  49. 8.9 Reddy's Laboratories
  50. 8.9.1 Reddy's Laboratories Company Information
  51. 8.9.2 Reddy's Laboratories Business Overview
  52. 8.9.3 Reddy's Laboratories Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
  54. 8.9.5 Reddy's Laboratories Recent Developments
  55. 8.10 Samsung Bioepis
  56. 8.10.1 Samsung Bioepis Company Information
  57. 8.10.2 Samsung Bioepis Business Overview
  58. 8.10.3 Samsung Bioepis Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
  60. 8.10.5 Samsung Bioepis Recent Developments
  61. 8.11 Samsung Bioepis Co., Ltd.
  62. 8.11.1 Samsung Bioepis Co., Ltd. Company Information
  63. 8.11.2 Samsung Bioepis Co., Ltd. Business Overview
  64. 8.11.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
  66. 8.11.5 Samsung Bioepis Co., Ltd. Recent Developments
  67. 8.12 Viatris
  68. 8.12.1 Viatris Company Information
  69. 8.12.2 Viatris Business Overview
  70. 8.12.3 Viatris Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Viatris Psoriasis Biosimilar Product Portfolio
  72. 8.12.5 Viatris Recent Developments
  73. 8.13 Pfizer Inc.
  74. 8.13.1 Pfizer Inc. Company Information
  75. 8.13.2 Pfizer Inc. Business Overview
  76. 8.13.3 Pfizer Inc. Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
  78. 8.13.5 Pfizer Inc. Recent Developments
  79. 8.14 Merck KGaA
  80. 8.14.1 Merck KGaA Company Information
  81. 8.14.2 Merck KGaA Business Overview
  82. 8.14.3 Merck KGaA Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
  84. 8.14.5 Merck KGaA Recent Developments
  85. 8.15 Sandoz
  86. 8.15.1 Sandoz Company Information
  87. 8.15.2 Sandoz Business Overview
  88. 8.15.3 Sandoz Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sandoz Psoriasis Biosimilar Product Portfolio
  90. 8.15.5 Sandoz Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst